News and Media

News and Media

  • Onxeo Reports its Full-Year 2021 Financial Results and announces additional financing of €12 million

    April 6, 2022

  • Onxeo to present new preclinical data highlighting AsiDNA™’s ability to fight tumor resistance and protect from anticancer treatment toxicity at AACR Annual Meeting 2022

    March 31, 2022

  • Onxeo’s new preclinical data confirm the relevance of combining AsiDNA™ with PARP inhibitors in treating homologous recombination proficient tumors

    March 9, 2022

  • Onxeo Announces its Financial Agenda for 2022

    January 13, 2022

  • Onxeo appoints Julien Miara as new interim CEO

    January 3, 2022

  • Onxeo Continues to Strengthen its Board of Directors

    November 23, 2021

  • New preclinical data confirm the ability of AsiDNA™ to tackle the drug-tolerant persister cells and prevent tumor resistance in several combination treatments

    August 12, 2021

  • Onxeo Receives Notice of Allowance from USPTO for New Patent Strengthening Protection of AsiDNA™ via Systemic Administration in the United States

    December 10, 2020

  • Onxeo Announces the Transfer of the Listing of its Shares to Euronext Growth Paris on December 15, 2020

    December 10, 2020

  • Onxeo Announces Completion of Patient Enrollment in DRIIV-1b Study and Positive Interim Results

    November 9, 2020

  • Onxeo Receives Notice of Intent to Grant a New Patent Enhancing the Protection in Europe of AsiDNA™ Combined with PARP Inhibitors

    October 22, 2020

  • Onxeo Announces Enrollment of First Patient in Phase Ib/II Study Revocan

    October 21, 2020

  • Publication of the 2020 Half-Yearly Financial Report

    September 29, 2020

  • Onxeo reports its financial results for the first half of 2020 and provides an update on its activities

    September 17, 2020

  • Onxeo to Attend Key Investor Conferences and Events in the Second Half of 2020

    September 8, 2020

Press Release Signup

Subscribe to receive our Press Releases when they come out.